CHECKPOINT-214 was stopped early for OS success in Sep 2017 (#msg-134437412), but the details were not disclosed until now.
CHECKPOINT-214 tested Opdivo+Yervoy vs Sutent and had three co-primary endpoints: ORR, PFS, and OS. In Aug 2017, BMY reported that the trial hit the ORR endpoint and missed on PFS (#msg-133869270).